EGFR and non-small cell lung carcinoma: Osimertinib, the third-generation of EGFR tyrosine kinase inhibitors (TKIs), can be used for the first-line treatment of patients with locally advanced or metastatic NSCLC, with mutations in exon 18–21 of EGFR (epidermal growth factor receptor) gene [1].